A tragic story has emerged from China, raising serious ethical concerns regarding medical research practices. In 2023, a 6-year-old girl received the world’s first gene-editing therapy targeting the central nervous system. However, just seven days after the procedure, the child died, prompting widespread outrage and a subsequent government investigation that revealed troubling aspects about the clinical trial.
On November 13, 2024, the Shanghai Municipal Government released the results of its investigation into the incident, resulting in several professionals being dismissed from their positions, including Qiu Zilong, the deputy director of the Shanghai Jiao Tong University School of Medicine’s Songjiang Research Institute, and Yang, the first author of the paper documenting the research. They have been banned from participating in scientific projects or awards for five years and have been included in a serious breach of research integrity database.
Additionally, the clinical study leader, Yu, was removed from his position as director of the research department and demoted by two levels. His involvement in research projects, awards, and graduate student admissions has also been suspended for five years. Other individuals connected to the hospital’s ethics committee and management have faced disciplinary action from the Party and administrative sanctions.
The case originated from a team led by Qiu Zilong at the Shanghai Jiao Tong University. The girl’s family had raised approximately $860,000 (around 5.82 million yuan) to fund this experimental clinical treatment, motivated by the girl’s rare neurodevelopmental disorder. Three days after the therapy, the child developed a fever, followed by severe kidney damage symptoms, leading to her untimely death about a week later.
Notably, the details of this case remained hushed until over a year later, when an investigative report published by *Science* revealed multiple discrepancies in the clinical research process, garnering external scrutiny.
Investigators have since reported that the published paper failed to disclose negative outcomes of the treatment and did not accurately reveal potential conflicts of interest. The nature of the punishments meted out by the authorities has faced critical examination, with many questioning the effectiveness of the responses. Comments from the public included skepticism toward the so-called “informed consent” documents, which some perceived as a shield for unethical practices. Others voiced outrage at the lack of criminal charges against those involved.
In commentary on the situation, an observer noted that the official penalties seemed insufficient and exemplified a broader problem within the Chinese Communist Party (CCP) system, which allegedly tolerates ethical violations. It has been suggested that the persistent promotion of atheism in Chinese education has led scientists to lack basic ethical considerations, creating an environment where such experiments can occur without proper oversight.
Prior reports from the Chinese Economic Observer indicated that the problem of superficial ethical reviews and illegal human experimentation is widespread, with this tragic incident merely surfacing due to its exposure by foreign media outlets. According to statements allegedly made in medical circles, the troubling practices documented in this case are far from isolated.
The investigation also revealed that Qiu and three other research team members had received about 1.06 million yuan in benefits from the girl’s family, with one individual, Yang, receiving approximately 900,000 yuan along with expensive liquor. Authorities have stated that these items have since been returned or surrendered.
Despite the detailed disclosures about the sanctions imposed on the researchers and responsible hospital officials, the report has been silent on whether the girl’s family has received any form of compensation or guidance regarding future remedies. For the family who lost their child, the sanctions against the research team do not equate to an acknowledgment of their grief or a resolution to their loss. The quest for justice and ethical accountability in medical research continues, provoking tough questions about the treatment of patients in experimental settings and the responsibilities of medical professionals.